To avoid CKD, the guidelines now provide detailed review of the risk/benefit profile comparing partial to radical nephrectomy.
Both urologists and nephrologists provide follow-up and continuity of care to patients after cancer nephrectomy.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
All patients with an SRM should be considered for a biopsy when the results may alter management.
The most common types of benign pathology were oncocytoma, angiomyolipoma, and complex cysts.
In 2013, nearly one third of all minimally invasive radical nephrectomies were performed with robotic assistance.
Robotic partial nephrectomy confers a superior morbidity profile compared to laparoscopic partial nephrectomy.
Study of US veterans reveals, however, that the procedure is being used less in subgroups who might benefit the most.
The recurrence group had significantly larger tumors than the no-recurrence group.
Open partial nephrectomy had a significantly higher rate of complications.
Patients whose surgical wait time was 3 months or more versus less than 3 months had 10-fold increased odds of having a smaller tumor.
Disseminated cancer at the time of radical nephrectomy is associated with 2-fold increased odds of major perioperative complications.
Most patients discharged home within first 6 hours after surgery; none readmitted.
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.
Cytoreductive nephrectomy (CN) use remained stable in the targeted therapy era, but more patients are receiving a combination of CN and systemic therapy.
Findings among patients on chronic antiplatelet therapy for cardioprotection.
Positive surgical margins are associated with a significant 34% increased risk of all-cause mortality.
Elevated neutrophil-to-lymphocyte ratio is associated with larger tumors and greater nuclear grade.
Nephron-sparing surgery decreased the risk of end-stage renal disease by 60% in select patients.
A retrospective study has shown that the procedure is feasible and was performed safely in selected patients with renal tumors.
Increased left ventricular mass found in donors with even mild decreases in renal function.
Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.
Active surveillance equal to partial nephrectomy for renal function preservation.
Review indicates that doctors who operate the night before another surgery do well.
Risk of postoperative complications increased for pediatric patients at non-high volume hospitals.
Radical and partial nephrectomy for renal cell carcinoma are associated with a similar risk of end-stage renal disease (ESRD), according to research.
Donor and recipient outcomes are similar to those associated with laparoscopic removal of left donor kidneys.
Individual cognitive factors accounted for half of all contributing human factor nano-codes.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Kidneys From Octogenarian Donors Show Similar Survival
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)